Table S1. Results of univariable Cox regression model analysis on RFS and OS.
| Variables | Before PSM | After PSM | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RFS | OS | RFS | OS | ||||||||||||
| HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | ||||
| Age | |||||||||||||||
| ≤60 | 1 | 1 | 1 | 1 | |||||||||||
| >60 | 1.275 | 1.001–1.623 | 0.049 | 1.524 | 0.992–2.341 | 0.054 | 1.146 | 0.862–1.524 | 0.347 | 1.111 | 0.666–1.853 | 0.688 | |||
| Sex | |||||||||||||||
| Male | 1 | 1 | 1 | 1 | |||||||||||
| Female | 0.841 | 0.615–1.149 | 0.277 | 0.933 | 0.541–1.608 | 0.802 | 0.88 | 0.605–1.279 | 0.502 | 1.063 | 0.566–1.996 | 0.85 | |||
| ASA score | |||||||||||||||
| II | 1 | 1 | 1 | 1 | |||||||||||
| III | 1.657 | 1.253–2.191 | 0 | 1.35 | 0.810–2.251 | 0.25 | 1.888 | 1.368–2.604 | 0 | 1.677 | 0.949–2.963 | 0.075 | |||
| Hypertension | |||||||||||||||
| No | 1 | 1 | 1 | 1 | |||||||||||
| Yes | 1.429 | 1.097–1.861 | 0.008 | 1.279 | 0.792–2.066 | 0.315 | 1.161 | 0.837–1.611 | 0.371 | 1.027 | 0.557–1.894 | 0.16 | |||
| Diabetes | |||||||||||||||
| No | 1 | 1 | 1 | 1 | |||||||||||
| Yes | 1.429 | 1.040–1.963 | 0.028 | 1.102 | 0.610–1.991 | 0.748 | 1.443 | 0.983–2.118 | 0.061 | 0.925 | 0.421–2.031 | 0.846 | |||
| Cardiopathy | |||||||||||||||
| No | 1 | 1 | 1 | 1 | |||||||||||
| Yes | 1.258 | 0.747–2.118 | 0.388 | 0.737 | 0.233–2.333 | 0.603 | 1.201 | 0.565–2.553 | 0.635 | 0.545 | 0.076–3.934 | 0.547 | |||
| Tumor number | |||||||||||||||
| Solitary | 1 | 1 | 1 | 1 | |||||||||||
| Multiple | 1.901 | 1.423–2.540 | 0 | 1.595 | 0.956–2.661 | 0.074 | 2.012 | 1.441–2.811 | 0 | 1.712 | 0.957–3.065 | 0.07 | |||
| Cirrhosis | |||||||||||||||
| No | 1 | 1 | 1 | 1 | |||||||||||
| Yes | 1.535 | 1.114–2.114 | 0.009 | 1.99 | 1.028–3.853 | 0.041 | 1.701 | 1.165–2.484 | 0.006 | 2.144 | 0.976–4.708 | 0.057 | |||
| HBV/HCV infection | |||||||||||||||
| No | 1 | 1 | 1 | 1 | |||||||||||
| Yes | 1.233 | 0.860–1.766 | 0.255 | 1.054 | 0.559–1.987 | 0.872 | 1.225 | 0.816–1.839 | 0.327 | 1.031 | 0.508–2.090 | 0.934 | |||
| Adjuvant chemoradiotherapy | |||||||||||||||
| No | 1 | 1 | 1 | 1 | |||||||||||
| Yes | 1.825 | 1.404–2.372 | 0 | 1.337 | 0.811–2.203 | 0.255 | 1.895 | 1.379–2.606 | 0 | 1.503 | 0.822–2.748 | 0.185 | |||
| AFP | |||||||||||||||
| <400 ng/mL | 1 | 1 | 1 | 1 | |||||||||||
| ≥400 ng/mL | 1.347 | 0.978–1.856 | 0.068 | 1.483 | 0.860–2.558 | 0.156 | 1.295 | 0.882–1.901 | 0.187 | 1.424 | 0.742–2.735 | 0.288 | |||
| TBIL | |||||||||||||||
| <34 mmol/L | 1 | 1 | 1 | 1 | |||||||||||
| ≥34 mmol/L | 1.085 | 0.729–1.616 | 0.688 | 1.4 | 0.723–2.711 | 0.318 | 1.211 | 0.776–1.888 | 0.4 | 1.463 | 0.695–3.076 | 0.316 | |||
| ALB | |||||||||||||||
| >35 g/L | 1 | 1 | 1 | 1 | |||||||||||
| ≤35 g/L | 1.318 | 0.974–1.784 | 0.073 | 1.977 | 1.224–3.195 | 0.005 | 1.438 | 1.016–2.035 | 0.04 | 2.335 | 1.360–4.008 | 0.002 | |||
| ALT | |||||||||||||||
| <40 U/L | 1 | 1 | 1 | 1 | |||||||||||
| ≥40 U/L | 1.096 | 0.860–1.398 | 0.458 | 1.223 | 0.794–1.885 | 0.361 | 1.196 | 0.898–1.592 | 0.221 | 1.466 | 0.887–2.423 | 0.135 | |||
| AST | |||||||||||||||
| <40 U/L | 1 | 1 | 1 | 1 | |||||||||||
| ≥40 U/L | 1.094 | 0.860–1.392 | 0.466 | 1.315 | 0.856–2.018 | 0.211 | 1.284 | 0.969–1.700 | 0.081 | 1.631 | 0.991–2.685 | 0.054 | |||
| Child–Pugh stage | |||||||||||||||
| A | 1 | 1 | 1 | 1 | |||||||||||
| B | 1.387 | 0.948–2.030 | 0.092 | 1.851 | 1.004–3.413 | 0.049 | 1.443 | 0.947–2.199 | 0.088 | 2.208 | 1.149–4.241 | 0.017 | |||
| Tumor size | |||||||||||||||
| <3 cm | 1 | 1 | 1 | 1 | |||||||||||
| ≥3 cm | 1.737 | 1.366–2.209 | 0 | 2.084 | 1.356–3.202 | 0.001 | 1.872 | 1.414–2.477 | 0 | 2.12 | 1.285–3.500 | 0.003 | |||
| TNM stage | |||||||||||||||
| I | 1 | 1 | 1 | 1 | |||||||||||
| II | 2.154 | 1.638–2.831 | 0 | 2.263 | 1.431–3.578 | 0 | 2.269 | 1.646–3.128 | 0 | 2.244 | 1.306–3.856 | 0.003 | |||
| Usage of NSAIDs | |||||||||||||||
| No | 1 | 1 | 1 | 1 | |||||||||||
| Yes | 1.194 | 0.932–1.529 | 0.162 | 1.156 | 0.742–1.804 | 0.521 | 1.108 | 0.825–1.488 | 0.495 | 1.195 | 0.708–2.017 | 0.505 | |||
| Anesthesia methods | |||||||||||||||
| LA | 1 | 1 | 1 | 1 | |||||||||||
| GA | 1.47 | 1.153–1.874 | 0.002 | 1.539 | 0.993–2.386 | 0.052 | 1.445 | 1.088–1.921 | 0.011 | 1.614 | 0.964–2.702 | 0.066 | |||
RFS, recurrence-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; ASA, American Society of Anesthesiologists; HBV, hepatitis B virus; HCV, hepatitis C virus; TNM, Clinicopathological stage; AFP, alpha-fetoprotein; TBIL, total bilirubin; ALB, serum albumin; ALT, Alanine transaminase; AST, aspartate aminotransferase; LA, local anaesthesia; GA, general anaesthesia; NSAIDs, Non-Steroidal Anti-inflammatory Drugs.